Investing In Ortho Pipeline Could Offset Pricing Pressures – Stryker, Zimmer
This article was originally published in The Gray Sheet
Executive Summary
Ortho-focused device firms Stryker and Zimmer hope plans to reinvest their cash into R&D and strategically planned acquisitions will help serve as a buffer against declining prices in the hip and knee replacement space.
You may also be interested in...
Stryker's Hong Kong Training Program To Tap "Perfect Storm" Demand For Orthopedic Devices
HONG KONG - Medical technology provider Stryker launched an orthopedic training program in Hong Kong to support the growing demand of its products for hip and knee replacements in China
Stryker Buys Target Neurovascular Biz From Boston Scientific For $1.5 Billion
Stryker will enter the neurovascular market and become segment leader through the $1.5 billion purchase of Target Therapeutics from Boston Scientific, the firms announced Oct. 28.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.